Winter A J, Rowe G E, Duncan J R, Eis M J, Widom J, Ganem B, Morein B
Department of Veterinary Microbiology, Cornell University, Ithaca, New York 14853.
Infect Immun. 1988 Nov;56(11):2808-17. doi: 10.1128/iai.56.11.2808-2817.1988.
A single vaccination of mice with a complex of porin and smooth lipopolysaccharide (porin-S-LPS) extracted from virulent Brucella abortus 2308 provided significant protection (P less than 0.01 to P less than 0.001) against challenge with the same strain, equivalent to that achieved by vaccination with living attenuated B. abortus 19. The porin-S-LPS vaccine given without adjuvant or in several adjuvants (trehalose dimycolate and muramyl dipeptide; the pluronic polymer L-121 and muramyl dipeptide; or complexed with Quil A in immunostimulating complexes) provided equivalent protection. In contrast, one vaccination with porin complexed with rough LPS (porin-R-LPS) from a rough mutant of strain 2308 provided no protection with any adjuvant tested. In one experiment, two inoculations with the porin-R-LPS resulted in a low level of protection, probably owing to priming of the animals for production of O-polysaccharide-specific antibodies. However, one vaccination with rough-strain porin covalently bound to purified O polysaccharide conferred protection equal to that obtained with natural complexes of porin-S-LPS or with living strain 19. A synthetic vaccine containing long chains of O polysaccharide was more effective than one prepared with short chains. Protective vaccines caused the formation of increased concentrations of circulating O-polysaccharide-specific antibodies, although there were individual exceptions to the quantitative association between O-polysaccharide-specific antibodies and protection. Antibodies specific for porin or R-LPS were found in negligible quantities in vaccinated mice. These results provide additional evidence that the O polysaccharide will constitute an essential component of an effective subcellular vaccine against B. abortus and that O-polysaccharide-specific antibodies play an important role in protective immunity in brucellosis.
用从强毒流产布鲁氏菌2308中提取的孔蛋白与光滑脂多糖复合物(孔蛋白-S-脂多糖)对小鼠进行单次接种,可提供显著的保护作用(P小于0.01至P小于0.001),以抵抗同一菌株的攻击,其保护效果等同于用减毒活疫苗流产布鲁氏菌19接种所达到的效果。未添加佐剂或添加几种佐剂(海藻糖二霉菌酸酯和胞壁酰二肽;普朗尼克聚合物L-121和胞壁酰二肽;或在免疫刺激复合物中与Quil A复合)的孔蛋白-S-脂多糖疫苗提供了同等的保护作用。相比之下,用来自2308菌株粗糙突变体的孔蛋白与粗糙脂多糖复合(孔蛋白-R-脂多糖)对小鼠进行单次接种,在测试的任何佐剂作用下均未提供保护作用。在一项实验中,用孔蛋白-R-脂多糖进行两次接种产生了低水平的保护作用,这可能是由于动物被致敏以产生O-多糖特异性抗体。然而,用共价结合纯化O多糖的粗糙菌株孔蛋白进行单次接种所提供的保护作用等同于用孔蛋白-S-脂多糖天然复合物或活菌株19所获得的保护作用。一种含有O多糖长链的合成疫苗比用短链制备的疫苗更有效。保护性疫苗导致循环中O-多糖特异性抗体浓度升高,尽管O-多糖特异性抗体与保护作用之间的定量关联存在个别例外情况。在接种疫苗的小鼠中,针对孔蛋白或R-脂多糖的特异性抗体数量极少。这些结果提供了额外的证据,表明O多糖将构成针对流产布鲁氏菌的有效亚细胞疫苗的重要组成部分,并且O-多糖特异性抗体在布鲁氏菌病的保护性免疫中发挥重要作用。